Friday, July 31, 2026

Apple’s OLED iPad Pro Boosts Global Shipments by 356% in Just One Quarter

In Q2, global OLED tablet panel shipments hit 4.11 million, up 356% year-over-year, driven by Apple’s iPad Pro launch.

Is Lee Jae Myung’s Government Endangering South Korea’s Security? Key Insights on North Korea’s Recent Missile Tests

The People Power Party criticizes President Lee's approach to North Korea, claiming it jeopardizes national security amid missile tests.

THE CRUEL GRIND: North Koreans Are Being Worked To Death Under Kim Jong Un’s ‘Self-Reliant’ Slave System

The Rodong Sinmun emphasizes the Gangwon Spirit, highlighting internal cohesion and preparations for the upcoming Party Congress in North Korea.

News1

Author's Latest

How Hanmi’s e-Label Service is Revolutionizing Drug Information Access for Patients

Hanmi Pharmaceutical launches an e-label service for medications, enhancing access to drug info while promoting sustainability.

Samsung Galaxy Card: Unlock 200 USD Bonus Rewards with New Credit Card Launch in the U.S.

Samsung introduces the Galaxy Card in the U.S., offering cashback rewards and discounts, enhancing user experience through Samsung Wallet integration.

Hugel Launches Letybo in India: What This Means for the Aesthetic Market in 2026

Hugel enters the Indian market with its botulinum toxin product Letybo, targeting a 9% share in the aesthetic sector this year.

Lunit Joins Global AI Consortium for Next-Gen Drug Development: What This Means for Precision Medicine

Lunit joins an AI consortium to enhance drug development through AI-driven pathology and biomarker analysis, collaborating with global firms.

Celltrion Group’s 2 Trillion KRW Investment: What It Means for Global Bio Manufacturing by 2032

Celltrion Group plans a 2 trillion KRW investment to enhance production capacity and establish a leading position in global biotech.

Celltrion Expands PFS Production Capacity to 70 Million: What This Means for the Global Market

Celltrion Pharmaceutical plans to invest 2 trillion KRW to expand its pre-filled syringe production capacity to meet global demand.

Regenerative Medicine Expanded to Four Diseases Including Knee Osteoarthritis; Medipost and CHA Biotech Seen as Potential Beneficiaries

The Korean government is easing regulations on regenerative medicine, boosting biotech, and enabling patient access to validated therapies.

From Preclinical Development to Licensing: JNPMEDI Aims to Accelerate K-Biotech Growth With AI

JNPMEDI emphasizes the need for Korea's biotech sector to enhance global commercialization and reduce clinical trial costs using AI.

NGeneBio Expands Blood Cancer Diagnostic Panel Supply to Seoul National University Bundang Hospital

NGeneBio expands its blood cancer diagnostic panel supply, achieving strong growth in South Korea and international markets.

AI Model Enables Detection of Breathing Abnormalities During Surgery Without Blood Draws

South Korean researchers developed an AI model for noninvasive monitoring of pediatric patients' arterial carbon dioxide during surgery.

“Can I Have a Baby Too?” Hospital Gives Hope to Mothers With Heart Valve Disease

A study highlights successful pregnancies for women with heart valve disease, emphasizing the need for multidisciplinary care and risk assessment.

How an 82-Year-Old Defied Odds: Successful Removal of Brainstem Cancer with Keyhole Surgery

An 82-year-old's brainstem tumor was successfully removed using minimally invasive surgery, restoring his motor function and independence.

How Celltrion’s Truxima Dominates the U.S. Rituximab Market: A 4-Month Winning Streak

Celltrion's Truxima leads the U.S. rituximab market for four months, gaining FDA interchangeability status, boosting growth prospects.

Breakthrough in MASH Treatment: How miRNA-10a Outperforms Resmetirom in Fat Reduction

RXBio's miRNA-10a shows superior efficacy over Resmetirom in treating MASH, reducing fat, fibrosis, and inflammation significantly.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.